Why have I gained weight on Mounjaro?

What the trial data actually shows about early weight changes

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults and tracked outcomes over 72 weeks. Average body-weight reduction at the highest dose reached around 20–21%. What that aggregate figure does not show is the week-by-week noise inside it. Some participants saw the scale rise or plateau during the first several weeks before a sustained downward trend emerged. That is not an anomaly; it is a normal feature of how biological systems respond to a new intervention.

Tirzepatide works by activating both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite. But none of that happens instantaneously. In the early weeks the medicine is adjusting your gut motility, your fluid balance is shifting, and your body may be holding more water than usual. The NHS medicines page for tirzepatide confirms that gastrointestinal effects, including constipation, are common at the start of treatment. Constipation alone can add a kilogram or more to your scale reading on any given morning. That weight is not fat.

Short-term gains, then, are often measurement artefacts rather than genuine tissue changes. Before concluding that Mounjaro is causing weight gain, it is worth ruling out the mundane explanations that have nothing to do with how the medicine is working, and if you have gained weight on Mounjaro and want to understand what may be driving that pattern, we cover the most common reasons in detail. If you are concerned about a broader pattern of not losing weight, the evidence-based picture is explored further on our page about why Mounjaro might not be producing the losses you expected.

Dose stage and appetite suppression: why where you are in titration changes everything

The 2.5mg starting dose exists to let your system settle, not to drive significant weight loss. This is by design. The prescribing schedule titrates the dose upward roughly every four weeks, and the appetite-suppressing effect strengthens meaningfully at each step. If you have gained weight during the 2.5mg or 5mg phase, that does not predict what will happen once you reach your maintenance dose.

A question our prescribers hear regularly is whether the medicine is simply not working. Often the honest answer is that treatment is still in its early chapters. The clinical guidance from NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. Six months. Not six weeks. Benchmarking your result against the full trial duration rather than the first month gives a more accurate picture of whether treatment is on track.

If you are earlier in the titration process, gaining a little weight is not the right moment to stop. It may simply mean your body has not yet reached the dose where appetite suppression becomes the dominant force. Talking to your prescriber about your current dose stage is the most useful next step, and our Mounjaro overview covers how the full titration schedule is structured.

Lifestyle factors that can counteract the medicine's effect

Tirzepatide reduces appetite, but it does not override every calorie consumed. Alcohol is a clinically relevant factor here: it is calorie-dense, it can lower the inhibition that normally helps you make careful food choices, and it does not trigger the same satiety signals as food. Many people find their appetite falls on Mounjaro but that alcohol remains just as appealing as before.

Ultra-processed foods present a different challenge. Research increasingly shows that highly processed products can drive eating past the point of satiety, partly because their texture, palatability and rapid absorption bypass the normal fullness cues that GLP-1 medicines amplify. If your diet has drifted toward convenience foods during treatment, it may be blunting the medicine's effect more than you realise. Our page on how to get the most from Mounjaro covers the dietary patterns that support treatment.

Sleep is less discussed but genuinely important. Poor sleep raises cortisol and ghrelin, both of which increase appetite and can promote fat storage. A few nights of disrupted sleep can be enough to tip the scales upward even if the medicine is working well in every other respect. These lifestyle factors are not moral judgements; they are biological levers, and understanding them as such is more useful than guilt. If the cost side of treatment is adding pressure and you are weighing up whether to continue, a transparent breakdown of what your treatment plan includes is on our Mounjaro pricing page.

Muscle gain, body composition and why the scale is an incomplete measure

One underappreciated reason the scale can rise during Mounjaro treatment is muscle gain. If you have returned to exercise, or increased your activity because reduced weight makes movement easier, you may be building lean tissue. Muscle is denser than fat: a kilogram of muscle takes up less space than a kilogram of fat, but it still weighs a kilogram. Someone simultaneously losing fat and gaining muscle can see little movement on the scale, or even a small rise, while their body composition improves substantially.

This is not a failure of treatment. It may actually represent one of the better outcomes. Body composition changes, waist circumference, how clothes fit, blood pressure readings and blood glucose levels are all more clinically meaningful than scale weight alone. If you are exercising regularly and the scale has nudged upward, it is worth checking whether other measures are moving in the right direction before concluding that Mounjaro has caused harm.

If you are unsure whether what you are experiencing represents a genuine problem with your treatment or a pattern worth investigating further, the broader context of weight gain on Mounjaro and how to interpret it is worth reading alongside this page. Our clinical team is available to discuss your individual picture through a consultation.